The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lenalidomide in solid tumor patients with inflammatory cancer cachexia: A multicenter, randomized, double-blind, proof-of-concept study of fixed dose or CRP-response-guided dose or placebo.
F. Strasser
Research Funding - Celgene
R. Oberholzer
Research Funding - Celgene
D. Blum
Research Funding - Celgene
M. Joerger
Research Funding - Celgene
C. Driessen
Research Funding - Celgene
S. deWolf-Linder
Research Funding - Celgene
S. R. Haile
Research Funding - Celgene
R. von Moos
Research Funding - Celgene
N. Zerkiebel
Research Funding - Celgene
A. Jatoi
No relevant relationships to disclose
R. Woelky
No relevant relationships to disclose
K. Fearon
No relevant relationships to disclose
T. Cerny
Research Funding - Celgene